Case Studies

Case Studies

Galectin Therapeutics (NASD: GALT) engaged AMP in January 2014 when the stock was trading around $8.00 per share with average daily volume about 125.7K shares per day. During a six-month engagement the stock traded as high as $19.11. We presented the company to our network of Registered Financial advisors/Stock Brokers/Small Funds, and Institutions.

Inovio Pharmaceuticals (NYSE: INO) engaged AMP in July of 2012; traded on the NYSE Markets. In July of 2012 the stock was traded at $1.76 post split / .42 cents pre split. The stock has been as high as $15.80 per share currently hovering a little under $9 per share after four years of partnering with AMP. We have increased retail participation and made introductions into multiple broker-dealers. We have introduced the company to over 5000 Registered Financial Advisors/Stock Brokers/Small Funds and Institutions. Inovio is a valued and current client of AMP. 

Oncosec Med, Inc. (OTC.QB:ONCS) was engaged In February of 2014. The stock was traded at $0.45 per share with a market-cap of $76 million dollars. We are currently presenting the company to our network of Registered Financial advisors/Stock Brokers/Small Funds, and Institutions. We have exposed the company to a network of Financial Professionals, while increasing the market presence. We have high expectations for the company for 2015.
Retrophin Inc., (OTB.QB: RTRX), engaged AMP February 15, 2013 when the stock traded at $4.73 per share. We presented the company to our network of Registered Financial Advisors/Stock Brokers/Small Funds, and Institutions. During the engagement RTRX traded as high as $9.99 per share. We exposed the company to Financial Professionals  while increasing the market presence. The stock went on to trade as high as $24.25 per share.